Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Share News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.01
Bid: 2.00
Ask: 2.15
Change: 0.055 (2.72%)
Spread: 0.15 (7.50%)
Open: 2.07
High: 2.07
Low: 1.91
Prev. Close: 2.02
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: ImmuPharma hits milestone; Shearwater contract

Wed, 13th Apr 2022 11:06

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

----------

AIM - WINNERS

----------

ImmuPharma PLC, up 59% at 9.00 pence, 12-month range 4.80p-10.90p. "Delighted" with positive data from the Lupuzor/P140 pharmacokinetic study, required by the US Food & Drug Administration, as part of the new optimised international Phase 3 trial of Lupuzor in lupus patients. Study shows PK study has met the key endpoints requested by the FDA. "This positive PK data now clears the path for commencement of all clinical studies within the P140 platform. In addition to lupus, there is a planned Phase 2a/3 pivotal trial in chronic inflammatory demyelinating polyneuropathy," company notes.

----------

Shearwater Group PLC, up 25% at 136.42 pence, 12-month range 70.00p-230.00p. Subsidiary Brookcourt Solutions wins "significant" new contract win to the potential value of up to about GBP21.0 million with unnamed "leading telecommunications and media company". Initial, secured value of the contract, across an initial three year term, is GBP12.9 million, with the contract including an option to extend by a further two years for a total additional value of about GBP8.0 million.

----------

AIM - LOSERS

----------

Amur Minerals Corp, down 13% at 1.50 pence, 12-month range 1.00p-3.90p. Notes no individual or entity tied to company's AO Kun-Manie mine have been sanctioned in any round of EU, UK and US sanctions against Russia. Mine is in far east of Russia. Also notes flow of funds supporting AO Kun-Manie continue and company has now ensured sufficient cash reserves for the subsidiary covering budgeted costs through the first half 2022. Previously, AO Kun-Manie funds have been delivered to cover a 30 to 45 day period. Does say, however, company's lead legal consul representation in Moscow, Bryan Cave Leighton Paisner, is suspending operations within Russia. Company is reviewing options for lead Russian legal representation.

----------

By Paul McGowan; paulmcgowan@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
13 Dec 2019 12:12

ImmuPharma To List On Life Sciences Heavy Brussels Index

ImmuPharma To List On Life Sciences Heavy Brussels Index

Read more
11 Dec 2019 14:54

ImmuPharma says not looking to raise funds

(Sharecast News) - AIM-listed specialist drug discovery and development company ImmuPharma insisted on Wednesday that it is not looking to raise funds.

Read more
11 Dec 2019 14:03

ImmuPharma Confirms It Will Not Raise Funds Despite Share Price Rise

ImmuPharma Confirms It Will Not Raise Funds Despite Share Price Rise

Read more
28 Nov 2019 16:26

ImmuPharma shares soar as it teams up with Avion on Lupuzor

(Sharecast News) - Specialist drug discovery and development company ImmuPharma announced a licence and development agreement with Avion Pharmaceuticals on Thursday, for the exclusive rights to 'Lupuzor' in the United States.

Read more
28 Nov 2019 12:02

Immupharma Shares Take Off On Lupuzor US Licencing Deal With Avion

Immupharma Shares Take Off On Lupuzor US Licencing Deal With Avion

Read more
28 Nov 2019 07:28

ImmuPharma licenses lupus drug Lupuzor to Avion in the United States

LONDON, Nov 28 (Reuters) - British pharmaceutical firm ImmuPharma said on Thursday it had signed a licensing and development agreement for Lupuzor, a first-in-class treatment for auto-immune disease Lupus, with U.S. company Avion Pharmaceuticals....

Read more
30 Sep 2019 10:40

ImmuPharma Loss Narrows Slightly, Focus On Lupuzor Regulatory Approval

ImmuPharma Loss Narrows Slightly, Focus On Lupuzor Regulatory Approval

Read more
28 Jun 2019 12:01

Immupharma Study Demonstrates Robust Safety Profile Of Lupuzor

(Alliance News) - Immupharma PLC on Friday reported analysis of the results from the study of Lupuzor, its lead programme for the potential breakthrough compound for Lupus, a potentially life drug

Read more
28 Jun 2019 10:27

ImmuPharma pleased with Lupuzor open-label study results

(Sharecast News) - Specialist drug discovery and development company ImmuPharma released the analysis of results from the open-label six month extension study from its original pivotal phase 3 trial of 'Lupuzor' on Friday.

Read more
26 Jun 2019 11:15

Immupharma raises ?2.66m from subscription agreement with institutional investor

(Sharecast News) - Drug discovery and development specialist Immupharma raised roughly £2.66m via a subscription agreement with institutional investor Lanstead Capital on Wednesday.

Read more
26 Jun 2019 10:14

Immupharma Raises GBP2.7 Million From Share Subscription With Lanstead

(Alliance News) - Immupharma PLC on Wednesday announced a 26.6 million share subscription to raise around GBP2.7 million at a price of 10 pence per share.The drug discovery and development

Read more
24 May 2019 11:47

Immupharma 2018 Loss Widens Amid Placing; Progresses On Pipeline

LONDON (Alliance News) - Drug development firm Immupharma PLC said Friday its 2018 loss widened amid share placing costs, whilst it continued to make "key" progress in its 2018, pretax a

Read more
7 May 2019 11:06

ImmuPharma Exploring European Listing For Combined French Businesses (ALLIPO)

LONDON (Alliance News) - ImmuPharma PLC is exploring the merger and possible separate listing of two French subsidiaries, it said Tuesday.Elro Pharma Sarl and Ureka Sarl are currently on a

Read more
1 Apr 2019 14:07

ImmuPharma Loses Exclusivity Period For Talks With Incanthera

LONDON (Alliance News) - ImmuPharma PLC on Monday said proposed partner Incanthera Ltd can now talk with other potential parties after an exclusivity period ended.In September, ImmuPharma a

Read more
14 Mar 2019 11:04

ImmuPharma struggles to convince investors in latest update

(Sharecast News) - Shares in ImmuPharma fell even further on Thursday, as the ailing drug development company struggled to give shareholders some reassurance about its future in an update.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.